Effects of Upper Arm and Breathing Exercise on Interleukin-6 in COVID-19 Patients
Downloads
Introduction: COVID-19 disease has become a comprehensive world issue and has been declared a significant threat to global health. Interleukin-6 (IL-6) is an important inflammatory marker and one of the triggers of the cytokine storm in COVID-19, where increased levels can be an independent predictor of COVID-19 mortality. This study aimed to observe the effect of upper arm and breathing exercises on IL-6 levels in severe COVID-19 patients.
Methods: The study design was quasi-experimental, with blood tests conducted before and after the examination. A total of 20 patients with confirmed COVID-19 were involved, divided into intervention and control groups.
Results: Blood tests to determine baseline IL-6 levels were performed in all patients. Patients from the intervention group were given upper arm and breathing exercises for ten days, twice a day, via video tutorials on mobile phones, while patients from the control group did not receive any exercises. Patients from the intervention group obtained mean pre- and post-exercise IL-6 levels of 42.38 ± 48.48 and 16.78 ± 18.29, respectively (p = 0.005).
Conclusion: Upper arm and breathing exercises showed significant changes in IL-6 levels in severe COVID-19 patients.
Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020; 323: 1061–1069. [PubMed]
Zhou F, Yu T, Du R, et al. Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. Lancet 2020; 395: 1054–1062. [PubMed]
World Health Organization (WHO). Clinical Management of Severe Acute Respiratory Infection when Novel Coronavirus (nCoV) Infection is Suspected. Geneva, https://www.who.int/publications/i/item/10665-332299 (2020).
Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: A Systematic Review and Meta-Analysis. Rev Med Virol 2020; 30: 1–9. [PubMed]
Danwang C, Endomba FT, Nkeck JR, et al. A Meta-Analysis of Potential Biomarkers associated with Severity of Coronavirus Disease 2019 (COVID-19). Biomark Res 2020; 8: 37. [PubMed]
Tarigan AP, Ananda FR, Pandia P, et al. The Impact of Short-term Combination of Limb Training and Pursed-lip Breathing in Chronic Obstructive Pulmonary Disease. Open Access Maced J Med Sci 2020; 8: 479–483. [Journal]
Zhao H-M, Xie Y-X, Wang C. Recommendations for Respiratory Rehabilitation in Adults with Coronavirus Disease 2019. Chin Med J (Engl) 2020; 133: 1595–1602. [PubMed]
Yang L-L, Yang T. Pulmonary Rehabilitation for Patients with Coronavirus Disease 2019 (COVID-19). Chronic Dis Transl Med 2020; 6: 79–86. [PubMed]
Cui W, Ouyang T, Qiu Y, et al. Literature Review of the Implications of Exercise Rehabilitation Strategies for SARS Patients on the Recovery of COVID-19 Patients. Healthcare; 9. Epub ahead of print 2021. [PubMed]
Rosyanti L, Hadi I. Respon Imunitas dan Badai Sitokin Severe Acute Respiratory Syndrome Corona Virus 2 : Literatur Review. J Kesehat Madani Med 2020; 11: 176–201. [Journal]
Lasky JA, Fuloria J, Morrison ME, et al. Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19. Adv Ther 2021; 38: 782–791. [PubMed]
Perrone F, Piccirillo MC, Ascierto PA, et al. Tocilizumab for Patients with COVID-19 Pneumonia. The Single-Arm TOCIVID-19 Prospective Trial. J Transl Med 2020; 18: 405. [PubMed]
Lescure F-X, Honda H, Fowler RA, et al. Sarilumab in Patients Admitted to Hospital with Severe or Critical COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet Respir Med 2021; 9: 522–532. [PubMed]
Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in Patients with Severe COVID-19: A Retrospective Cohort Study. Lancet Rheumatol 2020; 2: e474–e484. [PubMed]
Tania POA, Simamora D, Parmasari W, et al. Kadar Interleukin 6 (IL-6) sebagai Indikator Progresivitas Penyakit Reumatoid Arthritis (RA). J Ilm Kedokt Wijaya Kusuma 2014; 3: 40. [Journal]
Wardika IK, Sikesa IGPH. Pengukuran Interleukin-6 (IL-6), C-Reactive Protein (CRP) dan D-Dimer sebagai Prediktor Prognosis pada Pasien COVID-19 Gejala Berat: Sebuah Tinjauan Pustaka. Intisari Sains Medis 2021; 12: 901–907. [Journal]
Liu T, Zhang J, Yang Y, et al. The Role of Interleukin-6 in Monitoring Severe Case of Coronavirus Disease 2019. EMBO Mol Med 2020; 12: e12421. [PubMed]
Vepa A, Bae JP, Ahmed F, et al. COVID-19 and Ethnicity: A Novel Pathophysiological Role for Inflammation. Diabetes Metab Syndr 2020; 14: 1043–1051. [PubMed]
Bohn MK, Hall A, Sepiashvili L, et al. Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression. Physiology (Bethesda) 2020; 35: 288–301. [PubMed]
Hirano T. IL-6 in Inflammation, Autoimmunity and Cancer. Int Immunol 2021; 33: 127–148. [PubMed]
Apituley TLD, Pangemanan DHC, Sapulete IM. Pengaruh Olahraga terhadap Coronavirus Disease 2019. J Biomedik JBM 2021; 13: 111–117. [Journal]
Hammami A, Harrabi B, Mohr M, et al. Physical Activity and Coronavirus Disease 2019 (COVID-19): Specific Recommendations for Home-Based Physical Training. Manag Sport Leis 2022; 27: 26–31. [Journal]
Mohamed AA, Alawna M. Role of Increasing the Aerobic Capacity on Improving the Function of Immune and Respiratory Systems in Patients with Coronavirus (COVID-19): A Review. Diabetes Metab Syndr 2020; 14: 489–496. [PubMed]
Prabawa IMY, Silakarma D, Manuaba IBAP, et al. Chest Therapy and Breathing Exercise in COVID-19 Patient: A Case Report. Bali Med J 2021; 10: 495–498. [Journal]
Copyright (c) 2024 Amira Permatasari Tarigan, Aditya Sri Listyoko, Pandiaman Pandia, Andika Pradana, Putri Chairani Eyanoer, Sudirman Parningotan Sinaga, Yeni Vera, Ruby Firdaus, Adini Arifah Ramadhani
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under “the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (